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Background: Although muscular calf vein thrombosis (MCVT) is commonly seen in everyday practice, no treatment
guidelines are available. This study evaluated short-term and mid-term outcome of isolated symptomatic MCVT.
Method: We included prospectively and consecutively all patients referred to an outpatient clinic with isolated MCVT.
Clinical signs were pain or edema, or both, of the calf. Diagnosis was established with duplex ultrasound (DUS)
examination. Not completely occlusive and asymptomatic MCVTs were excluded. Patients were followed up clinically and
with DUS at 1, 3, and 9 months, and up to 36 months. Anticoagulant therapy at curative dosage associated with
compression was prescribed for 1 month and was extended for 2 additional months in case of incomplete recanalization
at 1 month or if risk factors for venous thromboembolism (VTE) were present.
Results: Included were 128 patients (78 women, 50 men) presenting with 131 MCVTs. Their mean age was 57.02 
15.36 years (range, 20 to 87 years). Thrombus was present in the soleal veins (SoV) in 73 patients (55.7%) and in the
medial gastrocnemius veins (MGV) in 58 (44.3%). Initial symptoms were isolated pain in the calf in 90 patients, isolated
edema of the calf in six, and pain plus edema in 32. Anticoagulant therapy was prescribed in 53 patients (41.4%) for 1
month, in 59 (46.1%) for 3 months, and in 13 (10.2%) for >6 months. At baseline, nine pulmonary embolisms (7%),
complicated with MCVT, were observed in six MGV patients (10.3%) and three SoV patients (4.1%; P  .18). Two
nonfatal hemorrhagic events occurred. Three patients died during the follow-up after anticoagulant therapy had been
discontinued. Recanalization of MCVT was considered complete at 1, 3, and 9 months in 54.8%, 84.7%, and 96% of cases,
respectively, with no significant difference between the MGV and the SoV groups. Twenty-nine VTE symptomatic
recurrences (PE, n 6; DVT including MCVT, n 23) were observed in 24 patients (18.8%), with similar figures in both
thrombosis groups: none at 3 months, 11 between 3 and 9 months and 18 between 9 and 36 months. No extension of
the MCVT or a recurrence of VTE was observed in patients treated with anticoagulant therapy. Twelve cases of superficial
thrombophlebitis occurred during the follow-up period.
Conclusion: This study confirms the place of MCVT in VTE disorders. Pulmonary embolism at the MCVT initial
diagnosis was not rare, and mid-term follow-up (mean, 26.7 months) revealed that 18.8% of patients had at least one VTE
recurrence. The treatment of acute MCVT needs to be standardized because no guidelines currently exist. ( J Vasc Surg
2007;46:513-9.)Duplex ultrasound (DUS) examination has evolved to
become the imagingmethod of choice for investigating calf
vein thrombosis. Most vascular laboratories in France
routinely assess the calf deep veins in patients suspected
of having an acute deep vein thrombosis (DVT) of the
lower limbs. Complications, including propagation of
thrombus to proximal veins, pulmonary embolism (PE),
and post-thrombotic abnormalities have been reported,
albeit sometimes with conflicting data, and the precise
prevalence of these complications remains unclear.1-12
In the calf, we distinguished13,14 the crural veins, in-
cluding the posterior tibial veins, the anterior tibial veins,
the peroneal veins, all paired, from the muscular or sural
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doi:10.1016/j.jvs.2007.04.040veins, including the soleal veins (SoV), the medial gastroc-
nemius veins (MGV) and the lateral gastrocnemius veins
(LGV). Although muscular calf vein thrombosis (MCVT)
has long been recognized15-18 and several publica-
tions5,9,10,17,19-21 have underlined its frequency, few stud-
ies have been published on this topic and no treatment
guidelines are available. Management of this disease re-
mains controversial, although MCVT is commonly seen in
everyday practice. The objective of this study was to evalu-
ate the short-term andmid-term outcome of isolated symp-
tomatic acute MCVT. The crural veins were not a part of
the study.
METHODS
This study was conducted between July 1997 and June
2004. Patients were referred from local general practitio-
ners to our outpatient Vascular Medicine Clinic for suspi-
cion of DVT in the lower limbs. We included prospectively
and consecutively all patients presenting with isolated
MCVT. Clinical signs were pain or edema, or both, of the
calf.
Patients with nonmuscular DVT associated with
MCVT were not included. We excluded patients with not
completely occlusive and asymptomatic MCVT to be sure
513
JOURNAL OF VASCULAR SURGERY
September 2007514 Gillet, Perrin, and Allaertto include only patients with acute vein thrombosis, pa-
tients with a contraindication to anticoagulant therapy, and
patients who could not be followed up to 9 months.
Diagnosis was established by DUS imaging. We used
the Vivid 3 scanner (Vingmed; GE Healthcare Technolo-
gies Waukesha, Wis) and a linear probe (frequency, 7.5
MHz; range, 5 to 10 MHz) to investigate the lower limbs
and a phased array probe (frequency, 2.5MHz; range, 2.25
to 5 MHz) to investigate the abdomen and pelvis. All the
deep veins in both lower extremities, including the calf
muscular veins, were examined from the vena cava to the
calf veins.
The following protocol was used to assess calf vein
thrombosis. The patient was seated at the edge of the
examining table with his or her legs hanging, resting on a
stool. The calf veins were imaged individually in both
longitudinal and transverse planes from the ankle to the
knee. The gastrocnemius veins were first identified near
their confluence with the popliteal vein and were followed
within the muscle belly down into the calf. MGV and LGV
were both assessed. The SoVwere found first just below the
sural triangle and were followed in both directions.10
The criteria used to confirm the diagnosis of MCVT
was incompressibility of the vein with probe pressure that
induced pain combined with the absence of venous flow,
spontaneous or with distal compression. Most often, an
intraluminal thrombus was visualized.
The clinical examination and the history identified clin-
ical signs and symptoms suggestive of DVT, the existence
of a triggering factor (surgery, trauma, lengthy air or car
travel), a symptom suggestive of PE, and also the patient’s
personal and family history of previous venous thrombo-
embolism (VTE). In case of a symptomof PE, a ventilation-
perfusion lung scan or a helical computed tomography scan
was performed.
Screening for risk factors in patients with MCVT in-
volved the routine investigations used in our VascularMed-
icine Clinic in patients presenting with any type of DVT.
The risk factors assessed included neoplasm, thrombo-
philia, iliac, femoral, or popliteal deep venous abnormality,
hormone replacement therapy, and obesity.
Ultrasound imaging of the abdomen and pelvis, a chest
radiograph, and investigation of the prostate to detect a
possible neoplasm were performed in men aged 50 years
old, with more specific investigations depending on clinical
findings to guide the choice of tests.
Screening for thrombophilia was performed in subjects
aged40 years old or in patients with a history of DVT. It
included measurement of protein C, protein S, antithrom-
bin, antiphospholipid (APL) antibodies, and screening for a
mutation in coagulation factor V (presence of factor V
Leiden) and factor II G20210A.
Abnormalities in the iliac, femoral, and popliteal veins
indicative of post-thrombotic syndrome (PTS) or primary
deep vein insufficiency (PDVI) were sought and identified
with DUS.22 PTS was differentiated from PDVI by the
demonstration of morphologic abnormalities in deep vein
trunks by venous DUS investigation, that showed evidenceof post-thrombotic venous wall or valvular thickening. The
criterion used for qualifying obstruction was the one de-
scribed by Rutherford et al23: total vein occlusion at some
point in the segment or 50% narrowing of at least half of
the segment. The criterion for reflux was the identification
of a deep venous reflux involving the popliteal vein of 1
second.22,24,25 In some patients, venography or DUS pre-
viously performed at the time of an acute episode provided
evidence of an initial DVT.
Women were asked about contraceptive method or
hormone replacement therapy of menopause, and body
mass index (BMI 28 kg/m2) was used to assess obesity.
Anticoagulant therapy at curative dosage and elastic
compression stockings exerting at least 15 mm Hg ankle
pressure were prescribed to all patients for 1 month. We
used fluindione to obtain an international normalized ratio
(INR) of between 2 and 3. Walking was advised. Anti-
coagulant therapy was extended 2 additional months when
DUS at 1 month showed incomplete recanalization of the
MCVT or if risk factors for VTE were present, including a
history of recurrent venous thrombosis, PTS, thrombo-
philia, and malignancy.
Patients were followed up both clinically and with DUS
at 1, 3, and 9 months. The objectives of these examinations
were:
1. to identify possible complications of anticoagulant therapy;
2. to seek clinical signs or symptoms, or both, of extension
of the initial thrombosis or a recurrence of VTE defined
as any new symptomatic event of PE, DVT, or MCVT
involving the vein initially thrombosed after its recana-
lization or involving another muscular calf vein, and
confirmed by DUS or radiography; and
3. to assess recanalization of the MCVT.
Recanalization was considered complete when no ab-
normality other than venous wall or valvular thickening was
observed in the DUS examination. In other cases, it was
recorded as incomplete. The risk factors for VTE were
collected and analyzed. After month 9, patients were fol-
lowed up clinically and with DUS up to month 36 to detect
a recurrence of VTE.
Statistics analysis. Data analysis was performed using
the SAS 8.2 software (SAS Institute, Cary, NC). Quantita-
tive variables were expressed as means standard deviation
and were compared with the Student t test or a nonpara-
metric test such as the Mann-Whitney Wilcoxon test. The
proportions of qualitative variables were tested with non-
parametric tests (Fisher exact test), and P  .05 was con-
sidered significant.
RESULTS
During the study period, 131 isolated MCVTs were
identified in 128 symptomatic patients, consisting of 78
women (60.9%) and 50 men (39.1%). The average age was
57.02  15.36 years (median, 57; range, 20 to 87 years).
Seventy-three thromboses (55.7%) involved the SoV, and
58 (44.3%) involved the MGV. Three patients presented
with both SoV and MGV thrombosis. We did not observe
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the right calf in 69 patients (53.9%) and in the left calf in 59
(P  .47). In 30 (23.4%) of 128 patients, the MCVT was
combined with superficial thrombophlebitis (ST) in the
calf. Initial symptoms were isolated pain in the calf in 90
patients, isolated edema of the calf only in six patients, and
pain combined with edema in 32 patients. Sixty patients
(46.9%) reported that they had had a previous DVT, con-
firmed or not.
A triggering factor was identified in 85 patients
(66.4%). The most common factors were previous surgery
in 23, trauma in 16, and a long car trip in 7 or lengthy air
travel in 6.
The risk factors for VTE were cancer in 7 patients
(5.5%), in all cases known at the time of the MCVT
diagnosis; thrombophilia in 19 (14.8%), including het-
erozygous factor V Leiden in 16, protein S deficiencies, in
2, protein C deficiency in 1, and APL antibodies in 1; both
heterozygous factor V Leiden and protein S deficiency in 1;
obesity in 29 (22.7%); and 20 (25.6%) women were receiv-
ing hormone replacement therapy (contraceptive in 13;
hormonal therapy of menopause in 7). No additional cases
of cancer were discovered during the follow-up. An abnor-
mality of the deep venous system (iliac, femoral, or popli-
teal vein) was identified in 12 patients (9.4%): 10 with PTS,
including reflux in 7, obstruction in 2, and reflux and
obstruction in 1; and 2 with PDVI.
The distribution of patients according to number of
thrombotic veins is listed in Table I, and the distribution of
patients according to the diameter of the venous lumen
filled by the clot is summarized in Table II.
In the MGV thrombosis group, the thrombosis in-
volved one to six veins, but 82.8% of patients presented
several veins involved by the thrombosis. The diameter of
the thrombosis measured in the transverse plane with DUS
varied from 5 to 17mm, and 58.6% presented a thrombosis
in which the diameter measured 8 mm. The thrombosis
was confined to the intramuscular segment of the vein in 35
patients (60.3%), an extension into the extramuscular gas-
trocnemius vein was observed in 23 (39.7%), and extension
Table I. Distribution of patients according to the
number of thrombotic veins*
Veins (n)
Patients, n (%)
MGVT SVT
1 10 (17.24) 41 (56.16)
2 25 (43.1) 23 (31.51)
3 7 (12.07) 7 (9.59)
4 15 (25.86) 2 (2.74)
5 0 0
6 1 (1.72) 0
Total 58 (100) 73 (100.00)
MGVT,Medial gastrocnemius vein thrombosis; SoVT, soleal vein thrombo-
sis.
*Every gastrocnemius or soleal vein identified individually by duplex ultra-
sound imaging was counted separately.of from 1 to 3 cm into the popliteal vein but withoutcomplete occlusion of this vein was observed in nine
(15.5%).
In the SoV thrombosis group, the thrombosis involved
one to four veins, but 56% presented with a thrombosis
limited to a single vein. The diameter varied from 5 to 14
mm, and 56.2% of patients presented with a thrombosis
with a diameter of 8 mm.
Anticoagulation therapy at a curative dosage was pre-
scribed for 1 month in 53 patients (41.4%), for 3 months in
59 (46.1%), and for6 months in 13 (10.2%) because they
presented with a PE or major risk factors for VTE. In three
patients, the duration of AT was not known.
Nine PEs (7%), clinically suspected and confirmed with
radiographs, which were complicated with MCVT, were
observed in the baseline examination: six (10.3%) of 58 in
the MGV group and three (4.1%) of 73 in the SoV group.
The difference was not significant (P  .18). No patients
with PE had PTS or PDVI. We did not observe a PE in the
three patients presenting with both SoV and MGV throm-
bosis. None of those patients died or presented severe
clinical signs or major abnormalities evidenced by labora-
tory methods.
PE was diagnosed with ventilation-perfusion lung scan
in eight patients and with helical computed tomography
imaging in one. The symptoms suggestive of PE were chest
pain in five patients and dyspnea in four. In addition, one
patient presented with hemoptysis. Regarding the features
of theMCVTs, eight of nine patients presented with two to
four veins involved by the thrombosis. In all patients, the
diameter of the venous thrombosis was 8 mm. In the
subgroup of the six patients withMGV thrombosis and PE,
the thrombus was confined to the intramuscular segment of
the vein in two patients, extended into the extramuscular
gastrocnemius vein in two, and into the popliteal vein in
two.
Follow-up of at least 1 month was achieved in 125
Table II. Distribution of patients according to the
diameter of the vein lumen filled by the clot
Diameter (mm)
Patients, n (%)
MGVT SVT
5 4 (6.90) 3 (4.11)
6 8 (13.79) 19 (26.03)
7 12 (20.69) 13 (17.81)
8 12 (20.69) 13 (17.81)
9 7 (12.07) 12 (16.44)
10 6 (10.34) 5 (6.85)
11 6 (10.34) 2 (2.74)
12 1 (1.72) 3 (4.11)
13 0 3 (4.11)
14 0 3 (4.11)
15 1 (1.72) 0
17 1 (1.72) 0
Total 58 (100) 73 (100)
MGVT,Medial gastrocnemius vein thrombosis; SoVT, soleal vein thrombo-
sis.(97.7%) patients (127 MCVTs), at least 3 months in 120
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110 (85.9%) patients (111MCVTs). Beyond 9 months, 94
patients (73.4%) were followed up with a mean of 26.7
months. There was no difference in the distribution of the
followed up patients in the SoV thrombosis and MGV
thrombosis groups at the different times (P was .12, .66,
.20 and .35 at 1, 3, 9, and beyond 9 months, respectively).
Three patients with SoV thrombosis died, but at the
time of death, anticoagulation therapy had been discontin-
ued. The cause of death was myocardial infarction in one
patient, aortic aneurysm rupture in another, and cachexia in
a patient with metastatic disease.
Two (1.56%) of 128 patients presented with a serious
but nonfatal hemorrhagic event: a patient with gastric
cancer required a blood transfusion for digestive bleeding,
and a hematoma in the upper limb occurred after venipunc-
ture in a patient whose INR was 4.8 (the fluindione dosage
was reduced and the hematoma did not require any specific
treatment).
Recanalization (Table III) was complete at 1, 3, and
9 months in 54.8%, 84.7%, and 96%, respectively, in all
MCVTs, without a significant difference between the
SoV thrombosis and MGV thrombosis groups at the
different times of follow-up. Table III shows that
the numbers of DUS performed at the three follow-up
visits were lower than the numbers of followed up pa-
tients because some patients in whom prolonged antico-
agulation therapy had been prescribed were not assessed
by DUS at every visit.
Twenty-nine symptomatic VTE recurrent events
(Table IV) occurred in 24 patients (18.8%): none at 3
months, 11 between 3 and 9 months, and 18 between 9
and 36 months. One patient presented with three VTE
recurrent events, and three patients with two events.
There was no significant difference in the SoV thrombo-
sis and MGV thrombosis groups comparing the numbers
of patients with VTE recurrences or the numbers of VTE
events. Two (8.3%) of 24 patients had PTS with reflux.
We did not observe extension of the MCVT or VTE
recurrence in patients treated with anticoagulant therapy.
Table III. Recanalization rate
Time period MGVT, % (n) SVT, % (n) P*
1 month 0.62
0 52.1 (25) 56.7 (38)
1 47.9 (23) 43.3 (29)
3 months 0.97
0 84.9 (45) 84.6 (55)
1 15.1 (8) 15.4 (10)
9 months 1.00
0 95.8 (46) 96.1 (49)
1 4.2 (2) 3.9 (2)
MGVT,Medial gastrocnemius vein thrombosis; SoVT, soleal vein thrombo-
sis; 0, complete recanalization (ie, no postthrombotic anatomic abnormality
except for venous wall or valvular thickening); 1, incomplete recanalization.
*Fisher exact test.Six nonfatal PEs were observed, four (6.9%) of 58 in theMGV thrombosis group and two (2.7%) of 73 in the SoV
thrombosis group (P  .40); as were 23 DVTs, including
19MCVTs. TenMCVTs (MGV, 5; SoV, 5) were observed
in the muscle in which the initial MVCT occurred after its
recanalization. In addition, 12 STs were identified during
the follow-up.
DISCUSSION
DUS is the imaging method of choice for the diagnosis
of DVT in symptomatic patients, including calf vein throm-
bosis. DUS has been reported to have a diagnostic sensitiv-
ity of 94% to 100%, a specificity of 91% to 100%, a positive-
predictive value of 80%, and a negative-predictive value of
94% for detection of crural vein thrombosis.4,9,12,26,27
Compared with contrast venography, DUS has an
overall sensitivity, specificity, and accuracy of 87% for
MCVT diagnosis.10,12 AlthoughMCVT is commonly seen
in everyday practice, few publications address this subject
and no treatment guidelines are available. We were not able
to determine the precise prevalence of isolated MCVT
diagnosed in our VascularMedicine Clinic during the study
period because the overall number of DVTs was not deter-
mined during the MVCT inclusion period. This prevalence
of all lower limb DVTs varies in publications10,19-21,28
between 12.5% and 25%. Labropoulos et al10 detected 742
DVTs (14%) in 5250 patients referred to the vascular
laboratory for clinical suspicion of DVT. An isolated calf
DVTwas detected in 282 limbs (33.8%) in 251. An isolated
MCVT was found in 113 limbs (SoV, n  57; MGV, n 
48; SoV plus VGM, n 8), yielding a prevalence of 15% of
all DVTs.
We observed a similar distribution between MGV and
SoV thrombosis in agreement with some publications.10,20
In other series,12,29 SoV thrombosis was more common. In
our series we observed that in 30 patients (23.4%), MCVT
was combined with a ST. This association is not surprising:
in a previous article30 we had identified that ST was fre-
quently combined with DVT and particularly with MCVT.
In our series, pain was the most common symptom
suggesting DVT in patients presenting with MCVT. Pain
was often severe and disabling especially with MGV throm-
bosis. Isolated edema was rare, observed in 4.7% (6/128).
The natural history of MCVT is poorly known.
Table IV. Venous thromboembolism recurrence events*
Initial
Thrombosis 9 months 9-36 months No. total (%)
MCVT (n  2) MCVT (n  5)
MGVT Crural (n  1) Crural (n  1) 14/58 (24.1%)
PE (n  1) Proximal (n  1)
PE (n  3)
MCVT (n  5) MCVT (n  7)
SoVT Crural (n  1) PE (n  1) 15/73 (20.5%)
PE (n  1)
MGVT,Medial gastrocnemius vein thrombosis; SoVT, soleal vein thrombo-
sis; MCVT, muscular calf vein thrombosis; PE, pulmonary embolism.
*No thrombosis occurred at 1 or 3 months.MacDonald et al12 included 219 isolated MCVTs in 185
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aim was to establish the incidence of propagation of un-
treated isolated MCVT into the deep veins of the calf and
thigh. Each patient was evaluated by DUS on the first day
of presentation, with a repeat examination of the involved
leg 5, 9, 14, 30, and 90 days later. At 3 months, 84 (38.4%)
of 219 thromboses were excluded because the patients
were lost to follow-up or for various other reasons (some of
them had had been treated with anticoagulant therapy).
During their study, 22 patients died, although none of
these deaths seemed related to thromboembolic events.
Postmortem examinations were not done, so the authors
reported that death from thromboembolism could not
definitively be ruled out. Within their 3-month follow-up,
22 (16.3%) of the 135 limbs with isolated MCVT had
thrombus extension to the level of adjacent tibial or pero-
neal veins or higher, 20 (91%) of 22 of which occurred
within 2 weeks of the initial DUS. Four (3%) of 135
extensions to the popliteal vein were identified.
In this series, recanalization of theMCVT seemed to be
less satisfactory than in our series. Indeed the MacDonald
et al study12 reported a complete recanalization at 1 and 3
months in 20.7% and 44.6% of MCVT, respectively, vs
54.8% and 84.7% in our series. One hypothesis to explain
this difference is that the patients in our series were treated
with anticoagulant therapy. However, we cannot exclude
that the assessment criteria were different in the two studies
given that we considered veins with simple wall thickening
as completely recanalized.We did not assess the presence or
absence of post-thrombotic reflux because patients with a
history of DVT were not excluded.
No treatment guidelines currently exist. Schwarz et al31
conducted a prospective, nonrandomized study including
84MCVTs. He investigated the outcome in two cohorts of
consecutive patients. The first received compression ther-
apy and heparin for 10 days at therapeutic doses, and the
second received compression therapy alone. In the 52
patients who received heparin at therapeutic dosage, no
progression to DVT occurred. A statistically significant
higher rate of progression into the deep calf veins (25%) was
shown in the 32 patients without anticoagulant therapy.
The studies by MacDonald et al12 and Schwarz et al31
showed that the rate of extension of the thrombosis was
high in patients not treated with anticoagulant therapy, and
suggested that in most of the patients, the extension oc-
curred early after the diagnosis.
The Seventh American College of Chest Physicians Con-
ference on Antithrombotic and Thrombolytic Therapy32 rec-
ommended that, “patients with acute DVT require long-
term anticoagulant treatment (. . .). This observation
applies to patients with proximal vein thrombosis and also
to patients with thrombosis confined to the deep veins of
the calf.” However MCVT was not specifically referenced
in this recommendation.
In our series, we did not observe extension or VTE
recurrence during the anticoagulant therapy period.
Even though the clinical significance of extension of the
thrombus into the deep veins is not clearly established, ourresults, reinforced by the results of MacDonad12 and
Schwarz et al,31 indicate thatMCVT should be treated with
anticoagulant therapy. The issue is to determine the mini-
mum duration of anticoagulant therapy to prevent the
extension of the venous thrombosis with no major risk of
bleeding. This risk depends on the duration of anticoagu-
lant therapy. With an INR target range of between 2 and 3,
the yearly risk of major bleeding is estimated at 3%.33 For
this reason, in our opinion, long-term anticoagulant ther-
apy as recommended in Chest32 seems excessive. In our
series we observed only two nonfatal bleeding events; both
occurred in frail patients: one hadmetastatic disease and the
other was 79 years old. We suggest that anticoagulant
therapy at a curative dosage, associated with compression
therapy and walking, is necessary to prevent an extension of
the thrombus into the deep veins, for at least 15 to 30 days
and probably longer when a risk factor for VTE is present.
Management without anticoagulant therapy could be used
in patients with a major risk for bleeding, but this would
require monitoring with repeated DUS examinations.
The association between MCVT and PE is controver-
sial. Three publications have reported PE in patients with
isolated MCVT with a prevalence of 15%, 37.5%, and 50%
respectively.20,21,29
● Guias et al20 conducted a retrospective study on 848
symptomatic DVTs of the lower limbs; 106 patients
(12.5%) presented with isolated MCVT (MGV, 48;
SoV, 50; MGV plus SoV, 8). In 106 patients with
symptoms suggestive of PE, 16 (15%) were diagnosed
with PE with radiographs. Although it was retrospec-
tive, this study confirmed the high prevalence of iso-
lated MCVT in patients with calf vein thrombosis and
showed a high rate of PE associated with isolated
MCVT.
● Ohgi et al29 analyzed a series of 33 distal DVTs in 28
patients. Fourteen patients presented with isolated
SoV thrombosis and two with isolated MGV throm-
bosis. Six (37.5%) of 16 symptomatic PEs (in all iso-
latedMCVTs) were diagnosed by lung perfusion scan-
ning or pulmonary angiography. All six patients had
isolated SoV thrombosis.
● Hollerweger et al21 identified 45 patients presenting
with isolated MCVT in a series of 179 DVTs of the
lower limbs. PE was diagnosed in 50% of the MCVT
patients, but the inclusion criteria used for investigat-
ing PEs were not clearly defined. A limitation of these
two studies is the small number of patients with
MCVT.
In our prospective series we have identified 7% of PEs,
all of which were nonfatal and with no clinical or hemody-
namic signs of seriousness. In designing this study we
discussed whether to include patients with MCVT compli-
cated by symptomatic PE at the initial examination. It is
indeed impossible to identify the precise location of the
venous thrombosis source of the PE. At the time of clot
migration, was the venous thrombosis confined to a mus-
cular vein, or was extension of the venous thrombosis into
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ble; the migration of a thrombus from the muscle can cause
a distal subsegmental PE. We decided to include patients
with PE in our study insofar as the inclusion criterion was
the identification of an isolated MCVT by DUS in sus-
pected patients for DVT of the lower limbs.
In our series, all patients with PE, except one, presented
with extended MCVTs (several veins involved by the
thrombosis), and all had a large venous thrombosis (diam-
eter8 mm). These data confirm the result of Ohgi et al29
results, because in that series, all patients with PE presented
a large SoV thrombosis measuring 7 mm.
It is difficult to estimate whether PE is more frequently
associated with MGV thrombosis or with SoV thrombosis.
In our series, the prevalence of PE seemed higher in pa-
tients with MGV thrombosis than in patients presenting
SoV thrombosis, but the difference was not significant.
Ohgi et al29 identified PE only in patients with SoV throm-
bosis. The distribution of PEs was similar in the two groups
of MCVT in Guias et al20 publication.
As we have previously discussed, it is impossible to
identify the precise origin of the PE. Are we entitled to
speak of embolic risk of isolated MCVT? We can only note
that in published reports, MCVT is associated with PE with
a prevalence of 7% to 50%.
The patient profile with MCVT does not appear to be
very different from the patient profile with any other DVT
location. A triggering factor was identified in 66.8% of
patients, the most frequent being surgery. The risk factors
for VTE identified in our series were similar to those
reported in other DVT publications. MCVT does not
always appear as an isolated VTE event in the patient’s life:
47% of patients reported that they had had a previous DVT
(confirmed or not), and post-thrombotic anomalies (iliac,
femoral, or popliteal vein) were identified in 8% of patients
at the initial DUS examination. Furthermore, we observed
a high rate of VTE recurrence (18.8%, with 6 PEs) with a
mean follow-up of 26.7 months, and we cannot exclude
that the real incidence of VTE recurrence was higher,
because 27% of patients (34/128) were not followed up
beyond 9months. Consequently, and regarding the PE risk
as well, MCVT should not be considered a minor venous
thrombosis.
Schwarz et al34 reported one case of recurrent MCVT
due to a venous aneurysm of the SoV. We also observed a
feature of aneurysm of the MGV in two patients who
presented a recurrent MGV thrombosis. The 12 STs ob-
served during the follow-up were not taken into account as
a VTE recurrence but suggest that some additional patients
had a thrombotic profile. We did not assess the risk factors
for VTE recurrence because we did not perform systematic
screening at the initial examination.
CONCLUSION
This study confirms that symptomatic PE is not rare
(7%) at the initial diagnosis of isolated MCVT, as shown in
previous publications. We did not observe any deaths re-
lated to venous thrombosis or anticoagulant therapy; a lowrate (1.5%) of nonfatal bleeding, and no extension of the
venous thrombosis or VTE recurrence at 3 months but a
high 18.8% rate of VTE recurrence after 3 months during
the follow-up period (mean, 26.7 months). These results
underline the need for clarifying the treatment of symp-
tomatic MCVT.
We suggest that, apart from patients who present with
a major risk of bleeding, symptomatic MCVT requires
anticoagulant therapy at curative dosage at least for a short
duration of 15 to 30 days, and probably longer when a risk
factor for VTE is present, to prevent extension of the
thrombus into the deep veins. Only additional prospective
and randomized studies with large sample sizes can provide
high-grade recommendations. In addition, the high inci-
dence of VTE recurrence underlines the need to follow
such patients as well as all patients with any type of DVT
and to prescribe the usual preventive measures.
We thank Steven Zimmet for his invaluable contribu-
tion in rereading the manuscript.
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Muscular calf vein thrombosis (MCVT) is commonly seen in
everyday practice, and as foam sclerotherapy gains dominance in
treatment of venous disorders, this condition will become more
prevalent. No treatment guidelines are available, so this study is
important.
One hundred twenty-eight patients with 131 MCVTs were
included in this study. Seventy-three (55.7%) had thrombosis of
soleal veins, and 58 (44.3%) had thrombosis of the medial gastroc-
nemius veins. In our experience with foam sclerotherapy, the
reverse incidence was seen.
Anticoagulation was prescribed (41.4%) for 1 month, 59
(46.1%) for 3 months, and 13 (10.2%) for 6 months or more. Nine
patients (7%) had pulmonary emboli confirmed. We have had nofoam sclerotherapy experience is only 0.003%. Six (10.3%) of the
patients with thrombi were in the medial gastrocnemius vein
group, and three (4.1%) were in the soleal vein group.
Recanalization of MCVT was complete at 1, 3, and 9 months
in 54.8%, 84.7%, and 96% of cases, respectively. Our experience is
similar except that venous reopening occurred much earlier. Per-
haps this was because we administered low-molecular-weight hep-
arin immediately when the diagnosis of MCTV was made.
This study confirms the importance of MCVT in venous
thromboembolic disorders, but because this is an initial large
report on this condition, the results should be confirmed by
additional studies. There is a definite need to standardize the
treatment of acute MCVT because no guidelines exist at this
time.
